Pancreatic Cystic Neoplasms

This page is designed only for learning purposes.
It is not dedicated for any medical use or patient care.
HBPSurG makes no claims of the accuracy of the information contained herein.​

Interactive Algorithms

Further Guidelines

International evidence-based Kyoto guidelines (2024)

ACG Clinical Guideline (2018)

Italian Consensus Guidelines (2014)

Further Readings

Optimal Surveillance Interval of Branch Duct Intraductal Papillary Mucinous Neoplasm of the Pancreas
Surveillance for Presumed BD-IPMN of the Pancreas: Stability, Size, and Age Identify Targets for Discontinuation
It is not necessary to resect all mucinous cystic neoplasms of the pancreas: current guidelines do not reflect the actual risk of malignancy
Presence of low-grade IPMN at the pancreatic transection margin does not have prognostic significance after resection of IPMN-associated pancreatic adenocarcinoma
Guidelines on Pancreatic Cystic Neoplasms: Major Inconsistencies With Available Evidence and Clinical Practice— Results From an International Survey
Verona Evidence-Based Meeting (EBM) 2020 on Intraductal Papillary Mucinous Neoplasms (IPMNs) of the Pancreas: Meeting Report
State‑of‑the‑art surgical treatment of IPMNs
Fukuoka-Negative Branch-Duct IPMNs: When to Worry? A Study from the French Surgical Association (AFC)
Pathologic Evaluation and Reporting of Intraductal Papillary Mucinous Neoplasms of the Pancreas and Other Tumoral Intraepithelial Neoplasms of Pancreatobiliary Tract Recommendations of Verona Consensus Meeting
Survival Analysis and Risk for Progression of Intraductal Papillary Mucinous Neoplasia of the Pancreas (IPMN) Under Surveillance: A Single-Institution Experience
Main-duct Intraductal Papillary Mucinous Neoplasm High Cancer Risk in Duct Diameter of 5 to 9 mm
error: Content is protected !!